Relapsed/Refractory
8 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) (NCT03439280) | Millennium Pharmaceuticals, Inc. | 2018-04-20 |
| Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement (NCT02952573) | University Health Network, Toronto | 2017-06-13 |
Track Relapsed/Refractory automatically
Every clearance here is in the API, with alerts when new ones post.